[Guidelines for the treatment of gastroesophageal reflux disease].

Jun Haeng Lee, Yu Kyung Cho, Seong Woo Jeon, Jie Hyun Kim, Na Young Kim, Joon Seong Lee, Young-Tae Bak, Society of Neurogastroenterology Korean Society of Neurogastroenterology

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Gastroesophageal reflux disease (GERD) is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. In the last decade, GERD has been increasing in Korea. Seventeen consensus statements for the treatment of GERD were developed using the modified Delphi approach. Acid suppression treatments, such as proton pump inhibitors (PPIs), histmine-2 receptor antagonists and antacids are effective in the control of GERD-related symptoms. Among them, PPIs are the most effective medication. Standard dose PPI is recommended as the initial treatment of erosive esophagitis (for 8 weeks) and non-erosive reflux disease (at least for 4 weeks). Long-term continuous PPI or on-demand therapy is required for the majority of GERD patients after the initial treatment. Anti-reflux surgery can be considered in well selected patients. Prokinetic agents and mucosal protective drugs have limited roles. Twice daily PPI therapy can be tried to control extra-esophageal symptoms of GERD. For symptomatic patients with Barrett's esophagus, long-term treatment with PPI is required. Further studies are strongly needed to develop better treatment strategies for Korean patients with GERD.

Original languageEnglish
Pages (from-to)57-66
Number of pages10
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume57
Issue number2
DOIs
Publication statusPublished - 2011 Feb 25
Externally publishedYes

Fingerprint

Gastroesophageal Reflux
Proton Pump Inhibitors
Guidelines
Therapeutics
Protective Agents
Antacids
Gastrointestinal Contents
Barrett Esophagus
Esophagitis
Korea
Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lee, J. H., Cho, Y. K., Jeon, S. W., Kim, J. H., Kim, N. Y., Lee, J. S., ... Korean Society of Neurogastroenterology, S. O. N. (2011). [Guidelines for the treatment of gastroesophageal reflux disease]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 57(2), 57-66. https://doi.org/10.4166/kjg.2011.57.2.57

[Guidelines for the treatment of gastroesophageal reflux disease]. / Lee, Jun Haeng; Cho, Yu Kyung; Jeon, Seong Woo; Kim, Jie Hyun; Kim, Na Young; Lee, Joon Seong; Bak, Young-Tae; Korean Society of Neurogastroenterology, Society of Neurogastroenterology.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 57, No. 2, 25.02.2011, p. 57-66.

Research output: Contribution to journalArticle

Lee, JH, Cho, YK, Jeon, SW, Kim, JH, Kim, NY, Lee, JS, Bak, Y-T & Korean Society of Neurogastroenterology, SON 2011, '[Guidelines for the treatment of gastroesophageal reflux disease].', The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, vol. 57, no. 2, pp. 57-66. https://doi.org/10.4166/kjg.2011.57.2.57
Lee, Jun Haeng ; Cho, Yu Kyung ; Jeon, Seong Woo ; Kim, Jie Hyun ; Kim, Na Young ; Lee, Joon Seong ; Bak, Young-Tae ; Korean Society of Neurogastroenterology, Society of Neurogastroenterology. / [Guidelines for the treatment of gastroesophageal reflux disease]. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2011 ; Vol. 57, No. 2. pp. 57-66.
@article{2c163feda4d34f029ac7313c36faa728,
title = "[Guidelines for the treatment of gastroesophageal reflux disease].",
abstract = "Gastroesophageal reflux disease (GERD) is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. In the last decade, GERD has been increasing in Korea. Seventeen consensus statements for the treatment of GERD were developed using the modified Delphi approach. Acid suppression treatments, such as proton pump inhibitors (PPIs), histmine-2 receptor antagonists and antacids are effective in the control of GERD-related symptoms. Among them, PPIs are the most effective medication. Standard dose PPI is recommended as the initial treatment of erosive esophagitis (for 8 weeks) and non-erosive reflux disease (at least for 4 weeks). Long-term continuous PPI or on-demand therapy is required for the majority of GERD patients after the initial treatment. Anti-reflux surgery can be considered in well selected patients. Prokinetic agents and mucosal protective drugs have limited roles. Twice daily PPI therapy can be tried to control extra-esophageal symptoms of GERD. For symptomatic patients with Barrett's esophagus, long-term treatment with PPI is required. Further studies are strongly needed to develop better treatment strategies for Korean patients with GERD.",
author = "Lee, {Jun Haeng} and Cho, {Yu Kyung} and Jeon, {Seong Woo} and Kim, {Jie Hyun} and Kim, {Na Young} and Lee, {Joon Seong} and Young-Tae Bak and {Korean Society of Neurogastroenterology}, {Society of Neurogastroenterology}",
year = "2011",
month = "2",
day = "25",
doi = "10.4166/kjg.2011.57.2.57",
language = "English",
volume = "57",
pages = "57--66",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "2",

}

TY - JOUR

T1 - [Guidelines for the treatment of gastroesophageal reflux disease].

AU - Lee, Jun Haeng

AU - Cho, Yu Kyung

AU - Jeon, Seong Woo

AU - Kim, Jie Hyun

AU - Kim, Na Young

AU - Lee, Joon Seong

AU - Bak, Young-Tae

AU - Korean Society of Neurogastroenterology, Society of Neurogastroenterology

PY - 2011/2/25

Y1 - 2011/2/25

N2 - Gastroesophageal reflux disease (GERD) is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. In the last decade, GERD has been increasing in Korea. Seventeen consensus statements for the treatment of GERD were developed using the modified Delphi approach. Acid suppression treatments, such as proton pump inhibitors (PPIs), histmine-2 receptor antagonists and antacids are effective in the control of GERD-related symptoms. Among them, PPIs are the most effective medication. Standard dose PPI is recommended as the initial treatment of erosive esophagitis (for 8 weeks) and non-erosive reflux disease (at least for 4 weeks). Long-term continuous PPI or on-demand therapy is required for the majority of GERD patients after the initial treatment. Anti-reflux surgery can be considered in well selected patients. Prokinetic agents and mucosal protective drugs have limited roles. Twice daily PPI therapy can be tried to control extra-esophageal symptoms of GERD. For symptomatic patients with Barrett's esophagus, long-term treatment with PPI is required. Further studies are strongly needed to develop better treatment strategies for Korean patients with GERD.

AB - Gastroesophageal reflux disease (GERD) is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. In the last decade, GERD has been increasing in Korea. Seventeen consensus statements for the treatment of GERD were developed using the modified Delphi approach. Acid suppression treatments, such as proton pump inhibitors (PPIs), histmine-2 receptor antagonists and antacids are effective in the control of GERD-related symptoms. Among them, PPIs are the most effective medication. Standard dose PPI is recommended as the initial treatment of erosive esophagitis (for 8 weeks) and non-erosive reflux disease (at least for 4 weeks). Long-term continuous PPI or on-demand therapy is required for the majority of GERD patients after the initial treatment. Anti-reflux surgery can be considered in well selected patients. Prokinetic agents and mucosal protective drugs have limited roles. Twice daily PPI therapy can be tried to control extra-esophageal symptoms of GERD. For symptomatic patients with Barrett's esophagus, long-term treatment with PPI is required. Further studies are strongly needed to develop better treatment strategies for Korean patients with GERD.

UR - http://www.scopus.com/inward/record.url?scp=79960924586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960924586&partnerID=8YFLogxK

U2 - 10.4166/kjg.2011.57.2.57

DO - 10.4166/kjg.2011.57.2.57

M3 - Article

VL - 57

SP - 57

EP - 66

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 2

ER -